George D. Yancopoulos joined Regeneron in 1989 as its Scientific Founder and is currently the Chief Scientific Officer and President of Regeneron Laboratories. He received his M.D. and Ph.D. in Biochemistry and Molecular Biophysics from Columbia University. In the 1990s, Dr. Yancopoulos was the 11th most highly cited scientist in the world, and in 2004 he was elected to both the National Academy of Sciences and the American Academy of Sciences. Dr. Yancopoulos, together with key members of his team, is a principal inventor and developer of Regeneron's four FDA-approved drugs – PRALUENT® (alirocumab) Injection, EYLEA® (aflibercept) Injection, ZALTRAP® (ziv-aflibercept) Injection for Intravenous Infusion, and ARCALYST® (rilonacept) Injection - as well as of Regeneron's foundational technologies for target and drug development, such as its proprietary TRAP technology, VelociGene® and VelocImmune®. These technologies have produced Regeneron’s robust pipeline of fully human antibodies targeting eye disease, cardiovascular disease, asthma and other allergic diseases, inflammatory conditions and cancer. In 2014, Dr. Yancopoulos and his team launched the Regeneron Genetics Center, a major new initiative in human genetic research.
Dr. Yancopoulos is an alumnus of the 1976 Science Talent Search. He joined the SSP Board of Trustees in 2013.